CME online

in association with the 8th Heart in Diabetes (HiD)

DM Associated CKD impact on Morbidity and Mortality - Prevention and Management

This is a CME Symposium Supported by an Educational Grant from Bayer
Provided By:

Administrated by:
This CME online educational activity is approved for a maximum of 1.75 AMA PRA Category 1 Credits ™..
Accreditation period: September 1, 2024 – September 1, 2025

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be emailed to you upon satisfactory completion of these documents.

DM Associated CKD impact on Morbidity and Mortality - Prevention and Management
Agenda

Introduction & Pre-CME Questions
Yehuda Handelsman, MD

The Multiplying Effect of T2D with CKD on the Spectrum of Heart Disease & Mortality
Darren K. McGuire, MD, MHSc

Modifying Cardiovascular Risk Associated with CKD in T2D with Finerenone
Peter Rossing, MD, DMSc

Guideline Recommended Therapy in Patients with Diabetic Kidney Disease
Matthew R. Weir, MD

Panel Discussion and Q&A: Reconciling Cardiologists & Nephrologists Treatment Approach; The Future Role of ns MRA
Panel: Matthew R. Weir, MD • Darren K. McGuire, MD, MHSc • Peter Rossing, MD, DMSc
Moderator: Yehuda Handelsman, MD

Faculty

Yehuda Handelsman, MD, FACC, FAHA, FACP, FNLA, FASPC, FAHA, MACE

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair Scientific Advisory Board
DCMi- Diabetes CardioRenal &
Metabolism Institute
Chair & Program Director 8th HiD
Tarzana, California

Darren K. McGuire, MD, MHSc

Cardiologist in the Division of Cardiology
Jere H. Mitchell, M.D. Distinguished Chair in Cardiovascular Science
Distinguished Teaching Professor of Medicine with Tenure
Lead Physician of the Parkland Health Cardiology Clinics
University of Texas Southwestern Medical Center
Deputy Editor of Circulation, Senior Editor of Diabetes and Vascular Disease Research
Co-editor of the textbook: Diabetes in Cardiovascular Disease: A Companion to Braunwald’s Heart Disease
Dallas, Texas

Peter Rossing, MD, DMSc

Professor Department of Clinical Medicine
University of Copenhagen
Steno Diabetes Center Copenhagen
Herlev, Denmark

Matthew R. Weir, MD

Professor and Chief, Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Program Description

Type 2 diabetes, kidney disease and heart disease share a common etiology involving hyperglycemia, mineralocorticoid receptor activation, oxidative stress, inflammation and fibrosis. In fact, T2D and CKD multiply their effect on the spectrum of heart disease & death. Both CKD and T2D are common, affecting 14% and 11% of the US population, respectively. Most alarmingly, nearly 40% of patients with diabetes also have CKD leading to significant cardiovascular events and debilitating often lethal heart failure. This satellite symposium will address the pathophysiology and impact of T2D & CKD on CVD and HF. The satellite will explore the complex challenges of treating these patients, it will examine the role of finerenone a non-steroidal MRA in reducing progression of CKD, HF, CVD and mortality. It will further review the contemporary approach to their management, highlighting the 3 or perhaps 4 pillars medical directed guideline therapy. The respective roles of Cardiologists & Nephrologists will be discussed reconciling their different treatment approaches.


Learning Objectives

Upon completion of this CME symposium, participants should be able to:

  • Describe the impact of CKD in T2D on CVD, HF and mortality.
  • Discuss the screening recommendations and diagnosing CKD in DM
  • Understand the role of finerenone in Modifying Cardiovascular Risk Associated With CKD in T2D
  • Understand the Efficacy of Combination Therapy of Finerenone with SGLT2i &/or GLP-1 RA
  • Develop and implement pillars-based treatment for the prevention and management of CKD progression in diabetes to reduce comorbidities and mortality.

    • Target Audience

    This This educational initiative is designed for cardiologists, nephrologists, endocrinologists, Diabetologists, primary care physicians, internists, and other healthcare professionals interested in the Epidemiology, pathophysiology of diabetes with CKD and the prevention of related morbidity and mortality.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc., is accredited by the ACCME to provide continuing medical education for physicians.

    PESI, Inc, designated this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s).

    For information please contact: [email protected] or 818 342 1889

    This is a CME Program Supported by an Educational Grant from Bayer